Pioneers in Neuroscience

MEDIA STATEMENT ON ADUHELM™

Responding to questions about post-marketing requirement and patient access.

U.S. FDA approves ADUHELM™ (aducanumab-avwa) for Alzheimer’s disease

Biogen and Eisai receive FDA accelerated approval for a new therapy targeting amyloid beta plaque.

A Letter from Biogen’s CEO on ADUHELM
How one woman found hope in the challenges of Multiple Sclerosis

When Mayu's doctor diagnosed her with MS, she faced the challenges of being a new mother and the fear of losing her ability to play the piano. She found support in her family and discovered that, even with physical struggles, she could still practice her music.

Update on Tofersen Clinical Program
2020 Year In Review: Our Commitment to Corporate Responsibility

In an unprecedented year, Biogen continued to accelerate action on key challenges of our time including equity and access, diversity and inclusion and climate and health. Read about our progress on advancing environmental, social and governance (ESG) priorities, and our goals for a healthier, more resilient and equitable future.

Biogen updates delivered to your inbox
6/23/21 4:09 PM EDT
EISAI and Biogen Inc. Announce U.S. FDA Grants Breakthrough Therapy Designation for LECANEMAB (BAN2401), an Anti-Amyloid Beta Protofibril Antibody for the Treatment of Alzheimer's Disease
View all news
Diversity, Equity and Inclusion

Biogen is committed to the power of diversity – in our organization and among our patients and customers. Diversity is an essential asset of complementary strengths and perspectives from which all benefit, and which must unite us, not divide us.

Where Science Meets Humanity

Science that transforms patient lives. Science that seeks to solve societal problems. Science that acts with purpose. Science that is inspired by the diversity and passion of our people. Discover where science meets humanity at Biogen.

Follow us on social media